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Background: The widespread use of artesunate-amodiaquine (ASAQ) for treating uncomplicated malaria makes it
important to gather and analyse information on its tolerability.
Methods: An individual-patient tolerability analysis was conducted using data from eight randomized controlled
clinical trials conducted at 17 sites in nine sub-Saharan countries comparing ASAQ to other anti-malarial treatments.
All patients who received at least one dose of the study drug were included in the analysis. Differences in adverse
event (AE) and treatment emergent adverse event (TEAE) were analysed by Day 28.
Results: Of the 6,179 patients enrolled (74% <5 years of age), 50% (n = 3,113) received ASAQ, 20% (n = 1,217)
another ACT, and 30% (n = 1,849) a non-ACT (combination or single-agent) treatment. Overall, 8,542 AEs were
recorded. The proportion of patients experiencing at least one gastro-intestinal AE on ASAQ was 43% (and higher
than that with artemether-lumefantrine and dihydroartemisinin-piperaquine at two sites), and was 23% for any
other AEs (not different from other treatments). Specifically, the risk of diarrhoea, vomiting, cough and weakness
was lower with artemether-lumefantrine; artemether-lumefantrine and dihydroartemisinin-piperaquine carried a
higher risk of pruritus, chloroquine-SP had a higher risk of nausea. Parasitological recurrence increased the risk of
occurrence of any AE. No other difference was detected. Comparing AE to TEAE in patients who had pre-treatment
occurrence and grades of intensity recorded, AEs were significantly more related to the pre-treatment prevalence
of the symptom (p = 0.001, Fisher test); AEs overestimated TEAEs by a factor ranging from none to five-fold.
The overall incidence of serious AEs (SAEs) with ASAQ was nine per 1,000 (29/3,113) and mortality was one per
1,000 (three deaths, none drug-related); both were similar to other treatments.
Conclusion: ASAQ was comparatively well-tolerated. Safety information is important, and must be collected and
analysed in a standardized way. TEAEs are a more objective measure of treatment-induced toxicity.
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Artemisinin-containing combination therapy (ACT) is
the World Health Organization (WHO) recommended
first-line treatment of acute uncomplicated Plasmodium
falciparum malaria [1]. One such treatment is artesunate
plus amodiaquine (ASAQ), which has been commercia-
lized and dispensed as either loose or co-blistered indi-
vidually formulated products (loose ASAQ), and, more
recently as a fixed-dose coformulation (ASAQ FDC: first
market authorization in 2007, WHO prequalified in
2008, included in the Essential Medical List (EML) in
2011).
Worldwide, ASAQ (in its various formulations) is the
second most widely used ACT. The volumes of ASAQ
FDC have increased from less than one million treat-
ment courses in 2007 to 41 million in 2010 [1], of which
some six million treatments in 2008, 25 million in 2009
and over 45 million in 2010 were purchased via inter-
national organizations [2,3]. Over 23 million treatments
of ASAQ WhintropTM FDC had been ordered by 2012
for the private sector of the seven African countries
(Ghana, Kenya, Nigeria, Niger, Tanzania, Madagascar,
Uganda) included in the AMFm (Affordable Medicines
Facilities - malaria) pilot phase (from 2010 to February
2012)[4]. By 2011 around 120 million of ASAQ FDC
treatments had been distributed in 21 countries [5].
Although ACT is regarded as highly effective and
generally well tolerated, safety remains largely under-
reported. Synthesizing available information using indi-
vidual patient data for randomized controlled trials
(RCTs) can help better define treatments in terms of
risk-profiling and risk-management. There is also a real
need to develop a standardized system for generating
and analysing tolerability data from anti-malarial drug
efficacy studies; while an excellent standardized system
for efficacy analyses exists, there is no equivalent for
safety and tolerability.
For this study, relevant information was retrieved from
randomized controlled trials (RCTs) identified through a
systematic review for which individual patient data were
made available. This analysis included a majority of chil-
dren under five years old from sub-Saharan Africa since




The analysis of tolerability was by intent-to-treat (ITT),
including all participants who were randomized to the
study medications and took at least one dose and
followed-up to Day 28. The primary study endpoint in
all the RCTs included in the analysis was efficacy.
Follow-up ceased at the time of parasitological failure
(either primary or recurrence), protocol violation, loss tofollow-up, and no tolerability data were recorded there-
after. Signs or symptoms were recorded at enrolment
(Day 0) and tolerability outcomes were recorded post-
treatment from Day 1 to Day 28 according to study
procedures.
Study sites, design and patients
The studies were identified through a systematic review
of clinical trials and personal contacts, regardless of lan-
guage or publication status (published, unpublished, in
press, reports). Published studies were identified through
electronic searches up to April 2007 of MEDLINE,
EMBASE, LILACS, the Cochrane Infectious Diseases
Group's trials register and the Cochrane Central Register
of Controlled Trials (CENTRAL) using the search terms:
malaria, amodiaquine, artesunate, and artemisinin. To be
included, studies were to be RCTs conducted in Africa
comparing any formulation of ASAQ to any other single
or combination treatment of uncomplicated falciparum
malaria with follow-up of at least 28 days [6].
For the studies meeting these criteria, investigators
were contacted to provide individual patient data and
datasets received were examined for inclusion.
Design of the included studies
Trials were all randomized comparative: one was
double-blinded [7], four were open label [8-11], and
three were single blinded [12-14]. All studies used meth-
ods to conceal allocation, gave treatment under supervi-
sion and followed patients up for 28 days. More details
on the studies methodological quality can be found
elsewhere [15].
Tolerability outcomes
The tolerability outcome measure was any treatment ad-
verse event (AE) and treatment-emergent adverse event
(TEAE) occurring within 28 days of starting treatment.
In each of the studies included, signs or symptoms were
actively screened during follow-up [7-14].
An AE was defined as any sign or symptom occurring
after the start of treatment (first drug intake), irrespect-
ive of whether that sign or symptom was present at
baseline or not, of its severity and drug-event
relationship.
A TEAE was defined as the worsening of the con-
dition - ie any occurrence of an abnormal condition
as compared to baseline in patients who either had a
normal condition pre-treatment or an abnormal condi-
tion that was of lower intensity than that recorded post-
treatment (worst grade reported at any time, irrespective
of whether it improved later). Intensity was graded
nought to four (absent, mild, moderate, severe, very
severe) - this analysis was only possible in the sub-group
of patients from the sites who graded signs and symptoms;
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follow-up but not at enrolment, therefore TEAEs could
not be analysed.
Serious adverse events (SAEs) were defined as events
that were fatal, life threatening or required admission to
hospital, irrespective of drug-effect relationship. Death
was also reported separately. The incidence of AEs and
TEAE were calculated for each study and treatment arm
after standardizing AE terminology (i) translating French
into English language (ii) including redness, swelling,
burning, itching, rash skin symptom (iii) grouping weak-
ness with fatigue and asthenia.
The disposition of the two components of the ASAQ
combination is very different; AS is rapidly absorbed and
eliminated (half-life <1 hour), while the estimated me-
dian (range) elimination half-life of desethyl-AQ (AQ ac-
tive metabolite) is around nine (seven to 12) days. The
same is also true for the other ACT. Therefore most of
the AEs will likely happen before Day 28.
Statistical analysis
Data were standardized for an ITT analysis. Incidences
(proportions of patients experiencing an event) were cal-
culated for each treatment group and each sign or symp-
tom and defined as the number of patients reporting the
event divided by the number of patients initially at risk
(exposed). As all studies did not provide information on
the exact day of the event, it was not possible to calcu-
late the overall time-to-event expressed as person-day to
calculate incidence rate ratios, and AEs and TEAEs were
analysed as a binary variable occurring per patient. The
risks of experiencing AEs/TEAEs with ASAQ compared
to other drugs were measured by using multivariate lo-
gistic regression. A random intercept for each site was
included when the Lagrange multiplier (LM) test [16]
was significant for heterogeneity in multivariate logistic
regression. Since the day or the date of occurrence of
the adverse event was not available for around 2,000
patients with information on event intensity, and in
order to control for differences in efficacy and account
for differences in the duration of follow-up between
treatment groups which could be due to potential differ-
ences in treatment efficacy, the last day of observation
was included in the logistic regression models with a
random effect on the site. The adjusted risks (AOR) of
these AEs and TEAEs were assessed according to the
patients’ age (continuous in year); parasitaemia at enrol-
ment (continuous, log-transformed); the last day of ob-
servation (continuous in day) and the treatment
(categorical).
An additional analysis comparing AE and TEAE was
included using the sub-group of patients with sign or
symptom recorded and graded both pre- and post-treat-
ment. Categorical data were compared using the chi-square or the Fisher exact test. The non-normally dis-
tributed correlation used the Spearman test and com-
pared by the Fisher test. Confidence intervals were
calculated at 95% (95%CI), and comparisons considered
significant when P < 0.05. Data were analysed using Stata
v10 (Stata Corp.).
ASAQ treatment regimens
The majority of the patients were treated with individu-
ally formulated (loose) AS and AQ. The target dose was
AS 12 mg/kg over three days and AQ 30 mg/kg over
three days except in Uganda where AQ was given at
25 mg/kg (Day 0: 10 mg/kg, Day 1: 10 mg/kg, Day 2:
5 mg/kg). The loose combinations ASAQ were given
based on body weight, while in two studies the fixed
combination (FDC) ASAQ was given based on age and
weight [11,14]. The loose combination was administered
once-a-day, while the FDC was given either once- or
twice-a-day [14].
Comparator treatment regimens
ACTs: AL (20 mg artemether/120 mg lumefantrine given
according to weight as one (5–14 kg), two (15–24 kg),
three (25–34 kg), and four (≥ 35 kg) tablets given twice
daily co-administrated with fat for 3 days); DP (2.3 mg/
kg/day dihydroartemisinin and 18.4 mg/kg piperaquine
for three days); AS + SP (AS 4 mg/kg/day; SP 25 mg/kg
of sulphadoxine and 1.25 mg/kg/of pyrimethamine
administered in a co-formulated tablet SP as a single
dose);
Non-ACTs: AQ+SP (AQ 10 mg/kg/day for three days
and SP 25 mg/kg of sulphadoxine and 1.25 mg/kg/of
pyrimethamine administered in a co-formulated tablet
SP as a single dose); CQ (25 mg/kg chloroquine over
three days) and SP; AQ mono-therapy (10 mg/kg/day
for three days); AS mono-therapy (AS 12 mg/kg over
five days).
Ethical issues
All studies have been approved by the relevant ethics
and institution review committees [7-14].
Results
Characteristics of included studies
A total of 6,179 patients was enrolled in eight studies
conducted at 17 sites in nine countries (Table 1):
(i) Two multi-country studies (n= 1,879): one compar-
ing ASAQ FDC (n=628, of whom 313 were administered
once and 315 twice daily) to AL (n= 312) in Mendong-
Cameroon; Tsiroanomandidy-Madagascar, Bancoumana-
Mali, Mlomp-Senegal [7]; and the other comparing loose
ASAQ (n=268) to AQ (n= 270) in Lambaréné-Gabon
and Oussouye-Senegal [8].
Table 1 Number and age of patients included in the analysis
Site and Country Reference Age (year) ASAQ AL AQ AQ+SP AS+ SP AS CQ+SP DP Total
Median Mininum Maximum
Burkina Faso [9] 2.0 0.5 5 750 750
Cameroon [7] 6.2 1.0 65 110 56 166
Gabon [8]* 5.5 1.3 11 108 110 218
Madagascar [9] 7.4 1.4 53 119 60 179
Mali, Boulouga [7] 4.7 0.9 24 135 68 203
Mali, Bancoumana [10] 3.0 0.6 56 252 249 252 753
Rwanda, Kicukiro [11]* 3.3 1.0 5 74 74 75 223
Rwanda, Mashesha [11]* 3.0 1.1 5 89 93 87 269
Rwanda, Rukara [11]* 2.1 1.0 5 89 91 90 270
Senegal, Keur-Socé [7] 9.0 1.0 15 264 128 392
Senegal, Mlomp [11]* 5.0 0.9 64 160 160 320
Uganda, Apac [13]* 1.8 0.5 47 174 183 185 542
Uganda, Jinja [13]* 3.6 0.5 65 189 186 168 543
Uganda, Tororo [13,14]* 1.6 0.5 56 398 204 181 166 949
Zanzibar, Kivungue [12] 2.5 0.5 7 148 149 297
Zanzibar, Micheweni [12] 2.1 0.5 5 54 51 105
Total 3.0 0.5 65 3113 716 270 808 249 252 519 252 6179
Legend: * studies including grading of intensity AQ, amodiaquine; AL, artemether-lumefantrine; AS, artesunate; DP, dihydroartemisinin-piperaquine; CQ, chloroquine; SP,
sulphadoxine-pyrimethamine.
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Pouytenga-Burkina Faso comparing ASAQ fixed dose
(FDC, n = 375) to the loose ASAQ combination (n = 375)
[9] and in Boulouga-Mali to compare loose ASAQ
(n = 252), AS (n = 252) and AS+ SP (n = 249)[10].
(iii) Two studies conducted in a single country with
multiple sites in Rwanda-Mashesha, Rukara, and Kicu-
kiro comparing loose ASAQ (n = 252) to AQ+SP
(n = 258) and DP (n = 252) [11]; and in Zanzibar-
Kivunge, and Micheweni to compare ASAQ (n= 202) to
AL (n = 200)[12].
(iv) Two different studies in Uganda used the same
protocol in three common sites: Apac, Jinja and Tororo
comparing loose ASAQ (n = 761) to AL (n = 204), AQ+
SP (n = 550), CQ+SP (n = 519)[13,14].
Individually, the sites enrolled between 174 and 949
patients treated with either ASAQ, which constituted
50% (n = 3,113) of the total patient population, or a com-
parator: another ACT (20%, 1,217/6,179) or non-ACT
(30%, 1,849/6,179) (Table 1). Studies took place from
February 1999 in Gabon [8] to December 2006 in Sene-
gal [7]; 74% of the patients (4,579/6,179) were children
aged between four and 59 months.
In all cases, allocation was concealed until after a pa-
tient had given written consent to participate in the
study. All treatments were supervised over the three-day
course. According to WHO recommendations, after
each dose, children were observed for 30 min and thedose was re-administered if vomiting occurred. Children
who repeatedly vomited their first dose of study medica-
tion were excluded from the study and referred for fur-
ther management.
Adverse events (AEs)
Overall 8,542 AEs of 14 different types were recorded
occurring in 6,179 patients receiving at least the first
treatment dose (Figure 1) – each individual not having
or having one or multiple AEs; specifically, 3,634 AEs
occurred in 3,113 patients treated with ASAQ and 4,908
AEs occurred in 3,066 patients treated with a compara-
tor. The overall median proportion of patients on ASAQ
experiencing at least one gastro-intestinal (GI) AE was
43% (ranging from 3% to 91%), or at least one other AE
was 23% (ranging from 1% to 80%).
Using random effects multivariate logistic regression,
the risk of experiencing any GI AE was lower with AL
(AOR 0.67, 95%CI 0.51-0.87, p = 0.003) and DP (AOR
0.66, 95%CI 0.45-0.97, p = 0.035) than with ASAQ,
resulting from differences seen in two sites only; the oc-
currence of GI AEs was significantly related to the risk
of parasitological recurrence (AOR 1.21, 95%CI 1.03-
1.41, p = 0.019); older patients were at lower risks for GI
(AOR 0.98, 95%CI 0.97-0.99, p = 0.032).
For other AEs, no difference between treatment groups
was detected. The risk was significantly related to the risk
of parasitological recurrence (AOR 1.48, 95%CI 1.24-1.76,
Figure 1 Flow chart of patients included in the analysis.
Zwang et al. Malaria Journal 2012, 11:260 Page 5 of 12
http://www.malariajournal.com/content/11/1/260p=0.001), age (older patients were at higher risks for other
AEs (AOR 1.03, 95%CI 1.01-1.04, p=0.001), and duration
of follow-up (AOR 1.01, 95%CI 1.01-1.02, p=0.037).
There was no difference between the loose and fixed
dose ASAQ combination; no other risk was detected.
Gastro-intestinal (GI) AEs
In patients treated with ASAQ (Table 2, Figure 2), the
incidence of anorexia was 36% (789/2,164), diarrhoeaTable 2 Adverse event (AE) incidence in ASAQ groups
Sign or Symptom Adverse Event (AE)















* The total number of patients was different since different signs or symptoms wer21% (526/2,483), abdominal pain 20% (280/1,368),
vomiting 16% (479/2,937), and nausea 6% (116/2,104).
In Rwanda [11], 11.5% of patients vomited ASAQ,
which was not different from 9.9% for DP (p = 0.565) but
lower than with AQ+SP (19.5%, p = 0.002). In
Burkina Faso [9], 1.9% patients (14/750) were withdrawn
from the study for drug-induced vomiting, eight (2.1%)
and six (1.6%) with FDC and loose ASAQ,















e screened across the studies.
Figure 2 Adverse events (AE) incidence, ASAQ groups.
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and AS/SP or AS. In a multi-centre study [8], six
patients in the loose ASAQ group and five in the AQ
group developed early, drug-induced vomiting, necessi-
tating alternative treatment. In the other multi-centre
study [7], 13% (122/941) of the patients vomited within
the first half-hour after treatment administration from
Day 0 to Day 2 (no difference between ASAQ and AL).
In Uganda and Zanzibar drug vomiting and other later
vomiting were reported together [12-14].
Overall (all treatment groups), multivariate analysis for
each GI AE showed that compared to ASAQ (Figure 3),
patients treated with AL were at lower risk of diarrhoea
(AOR 0.68, 95%CI 0.52-0.90, p = 0.006, resulting from a
significant difference in Zanzibar) and vomiting (AOR
0.36, 95%CI 0.25-0.52, p = 0.001, resulting from significant
differences in patients treated in Uganda and Zanzibar),
while patients treated with CQ+SP were at higher risks
of nausea (AOR 2.67, 95%CI 1.35-5.27, p = 0.005).
Other risk differences were related to age: older
patients were at lower risk for vomiting, anorexia and
diarrhoea, and at higher risk for abdominal pain
(p < 0.005 for all comparisons); the risk of anorexia
(AOR 1.28, 95%CI 1.08-1.52, p = 0.005) was higher in
patients with a parasitological recurrence as well as the
risk of diarrhoea (AOR 1.28, 95%CI 1.07-1.54, p = 0.007),
which increased over time (AOR 1.02, 95%CI 1.01-1.04,
p = 0.001).
Other AEs
The incidence of headache on ASAQ was 9% (164/
1,739) increasing with age (AOR 1.21, 95%CI 1.14-1.28,
p = 0.001) and higher in patients treated with CQ+SP
(AOR 1.87, 95%CI 1.13-3.09, p = 0.015) than ASAQ.Dizziness was infrequent (1%) in all groups. One case (in
848) of mild tinnitus was reported with loose ASAQ on
the day of recrudescence (Day 21). Patients treated with
CQ+SP (4%, 7/160) were at higher risks for this hearing
disturbance compared to ASAQ (AOR 37.81, 95%CI
3.80-376.69, p = 0.001). Romberg test and nystagmus
were negative in all the patients screened (398 and 1592,
respectively). The incidence of pruritus was 19% (193/
1636) with ASAQ; the risk was comparatively higher
with AQ+SP (AOR 1.43, 95%CI 1.08-1.90, p = 0.013)
and AL (AOR 1.48, 95%CI 1.06-2.06, p = 0.021). The in-
cidence of skin conditions (redness, swelling, burning,
itching, rash) was 16% (118/759) on ASAQ (not different
from other groups).
The incidence of weakness with ASAQ was 20% (539/
2,749), and the risk was higher in patients with a para-
sitological failure (AOR 1.78, 95%CI 1.46-2.17, p = 0.001)
and lower in patients treated with AL, resulting from a
significant incidence difference found in Madagascar
(AOR 0.62, 95%CI 0.44-0.88, p = 0.006) (Figure 3). The
incidence of myalgia (muscle pain) was 8% (17/217) with
no difference between treatment groups.
Cough was the second most frequent AE reported for
ASAQ (29%, 509/1,747). No difference between treat-
ments was detected, but older patients were at lower
risks (AOR 0.92, 95%CI 0.90-0.95, p = 0.001), and the
risk increased during the follow-up (AOR 1.05, 95%CI
1.03-1.07, p = 0.001). Jaundice was infrequent (<1%) in
all groups.
AE and TEAE
In this sub-group, 3,943 TEAEs or 6,294 AEs occurred
in 3,334 patients who had received at least one treat-
ment dose (Figure 1). Some 1,493 TEAEs or 2,426 AEs
Figure 3 Adverse events (AE) forest plots, ASAQ vs. comparator treatments. AOR, adjusted odds ratio for age, log parasitaemia,
parasitological reappearance, and treatments, randomized by site; CI, confidence interval; AQ, amodiaquine; SP, sulfadoxine-pyrimethamine; DP,
dihydroartemisinin-piperaquine; CQ, chloroquine; AS, artesunate; AL, artemether-lumefantrine; ASAQ F, artesunate amodiaquine fixed dose
combination.
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TEAEs or 3,868 AEs in 2,053 patients treated with com-
parator drugs.
Using multivariate analysis, compared to ASAQ,
patients treated with DP were at lower risk for GI AEs
or TEAEs (AOR 0.66, 95%CI 0.45-0.97, p = 0.035, AOR
0.50, 95%CI 0.32-0.79, p = 0.003, respectively), while
patients treated with AQ were at lower risk for GI
TEAEs (AOR 0.57, 95%CI 0.33-0.98, p = 0.041) but not
AEs (p = 0.927). For any other AEs or TEAEs, no differ-
ence between treatments was observed. Older patients
were at significant lower risks for gastro-intestinal AE
and TEAE. Between-treatment comparisons for each
TEAE are presented using forest plots in Figure 4.Difference between AEs and TEAEs on ASAQ treatment
The incidence of AEs and TEAEs following ASAQ treat-
ment is presented in Table 3, and Figure 5. Both AEs
and TEAEs incidences were correlated with the preva-
lence of the respective signs/symptoms at enrolment
(r = 0.86, p = 0.001, r = 0.66, p = 0.001, respectively, Spear-
man test), which was comparatively stronger for AEs
than TEAEs (p = 0.001, Fisher test). There was also a sig-
nificant relationship between admission at enrolmentand the difference in incidence between AE and TEAE
(r = 0.85, p = 0.001, Spearman test).
The comparison between prevalence of signs/symptoms
on admission and AE and TEAE intended to quantify
the difference in appreciation of drug tolerability when
reporting TEAEs or AEs (i.e. whether accounting for pre-
treatment intensity of signs/symptoms).
Table 3 presents the prevalence of signs/symptoms at
enrolment and compares their incidence post-treatment
when reported as AEs or TEAEs. Except tinnitus and
jaundice, all other events were more frequent by a factor
of 22%-399% when reported as AEs than TEAEs.
For GI events, the prevalence of diarrhoea at enrol-
ment was 20%; the incidence of AEs and TEAEs was
25% and 17% respectively, and the difference between
the two was +47% (meaning that 8%, n = 101, of the
patients had at least one episode of diarrhoea with the
same or decreasing intensity at any time during follow-
up compared to pre-treatment). For nausea (18% at en-
rolment), the difference between AE and TEAE was
+386%.
For neurological effects, headache was common at
enrolment (46%) and decreased post-treatment (inci-
dence of AE= 18%, TEAE= 3%, difference +388%). Both
dizziness and tinnitus were infrequent at enrolment and
Figure 4 Treatment emergent adverse event (TEAE) forest plots, ASAQ vs. comparator treatments. AOR, adjusted odds ratio for age, log
parasitaemia, parasitological reappearance, time, and treatments, randomized by site; CI, confidence interval; AQ, amodiaquine; SP, sulfadoxine-
pyrimethamine; DP, dihydroartemisinin-piperaquine; CQ, chloroquine; AS, artesunate; AL, artemether-lumefantrine.
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prevalence of pruritus was 26% pre-treatment, and the
incidence of AEs and TEAEs was 25% and 19% (differ-
ence +36%), meaning that 6% of the patients had theTable 3 Incidence of treatment emergent adverse events (TEA









Neurological Headache 736 46%
Dizziness 519 2%
Tinnitus 200 1%
Dermatological Pruritus 756 26%
Skin symptom 759 24%




* The total number of patients was different since different signs or symptoms wersame or decreasing symptom intensity during follow-
up.
Regarding other signs or symptoms, cough was the
most frequent at enrolment (69%); 16% (33%, TEAE;Es) and adverse events (AEs) patients treated with ASAQ
at TEAE AE AE vs TEAE
n Incidence n Incidence Relative
difference
217 17% 551 43% 154%
66 9% 202 27% 206%
188 15% 392 31% 108%
214 17% 315 25% 47%
22 3% 107 15% 386%
27 4% 132 18% 388%
3 1% 15 3% 399%
1 1% 1 1% 0%
141 19% 192 25% 36%
97 13% 118 16% 22%
248 33% 371 49% 50%
176 16% 470 42% 167%
17 8% 21 10% 24%
4 1% 4 1% 0%
e screened across the studies.
Figure 5 Relationship between the condition before treatment and after treatment using AE or TEAE definition, ASAQ groups. AE,
adverse event; TEAE, treatment emergent adverse event.
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stable intensity. Weakness was also very frequent at en-
rolment (59%) with 26% of patients with a decreasing or
stable intensity post-treatment. Muscle pain was quite
frequent at enrolment (32%), and there was no signifi-
cant difference between TEAE (8%) and AE incidence
(10%); most of the patients developing muscle pain after
treatment did not have that symptom at enrolment,
while others recovered. Jaundice was infrequent (<1%,
4/759).Deaths
Overall six deaths occurred in the studies, corresponding
to a mortality of one per 1,000 (3/3,113) with ASAQ, as
well as with comparators (3/3,066). None of them was
attributed to the study treatment. In Senegal [7] two
patients died: one who received ASAQ had lung infection
and anaemia on Day 3; the other one received AL group
and died of fatal coma of unknown cause on Day 1.
Two male patients in Pouytenga-Burkina Faso,
recruited for uncomplicated malaria and treated with the
loose and FDC ASAQ respectively, died of severe cere-
bral malaria occurring after the first day of treatment [9].
One patient (nine months old, 6 kg, 38°C, 1,651 pct/μL,
Hb: 12.3 g/dL, and no gametocyte at enrolment) died of
severe malaria at home. According to the parents, apart
from fever, no other symptom was observed and no other
drug was given. The other patient (25 months old, 11 kg,
11,224 pct/μL, Hb: 6.8 g/dL) was hospitalized at night
time with hyperpyrexia (39°C). He had upper limbs
hypertonia, was unconscious and convulsed, and died in
the afternoon after receiving parenteral quinine, diaze-
pam, phenobarbitol, and noramidopyrine. The death was
diagnosed as cerebral malaria.
In Uganda [13], two patients died: one of suspected se-
vere malnutrition and the other one of congestive heartfailure caused by a suspected congenital heart defect
(both patients had received AQ+SP).
No deaths occurred in the studies included in the
studies conducted in Gabon and Senegal [8] Mali [10],
Rwanda [11], Zanzibar [12], or in Uganda, Tororo [14].
Other serious adverse events (SAEs)
The incidence of other SAEs (except deaths) was nine
per 1,000 (29/3,113) with ASAQ and six per 1,000 (18/
3,066) with comparators (p = 0.124).
In Burkina-Faso [9], SAEs occurred in eight patients
within the first three days of treatment except for one
patient, who had gastroenteritis requiring hospitalization
for rehydration on Day 11. With ASAQ FDC these were:
two patients with convulsions (severe malaria) and one
child with gastroenteritis. With the loose ASAQ, the
SAEs were: one patient with convulsions and anaemia
(severe malaria), one patient with severe prostration
(severe malaria), and two patients with acute respiratory
distress (consistent with either malaria-induced meta-
bolic acidosis or pneumonia). All SAEs were considered
unrelated to the study drugs.
In Rwanda [11] one seizure with ASAQ, and one with
AQ+SP were reported.
In Uganda [13] 20 SAEs were reported in 16 patients
(four loose ASAQ, four CQ+SP, eight AQ+SP,
p = 0.40). SAEs included anaemia (two AQ+SP, one
loose ASAQ), convulsion (one CQ+SP, two AQ +
SP, one loose ASAQ), dehydration (one loose ASAQ),
oedema (one AQ+SP), malnutrition (one CQ+SP),
mental status change (two AQ+SP), respiratory distress
or infection (one CQ+SP, two AQ+SP, one loose
ASAQ), vomiting (one CQ+SP), and weakness (one
AQ+SP).
In Uganda [14] SAEs occurred in two participants: one
child treated with ASAQ developed pneumonia on Day
27, requiring hospitalization (unrelated to study drug),
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a convulsion on Day 0 judged to be unlikely to be
related to the study medication).
In Mali [10], two SAEs were reported: one case of se-
vere anaemia (AS) and one case of respiratory distress
and severe anaemia (ASAQ). Both patients were referred
to the Regional Hospital and recovered fully.
In a multi-centre study [7], four patients reported
SAEs after taking ASAQ. One case of severe anaemia
required hospitalization (related to treatment according
to the investigator). This event occurred on Day 7 of
follow-up and the patient recovered after hospitalization.
Three patients in the ASAQ group discontinued the
study due to SAEs (persistence of severe vomiting, fa-
tigue, vertigo and asthenia). These events were consid-
ered by the investigator to be probably related to
treatment. All patients recovered.
In Senegal and Gabon [8], three patients reported
SAEs after AQ or loose ASAQ: two patients had convul-
sions; one had asthma, one vomiting after the first drug
intake, and one had gastroenteritis. All SAEs were
regarded as unrelated to study drugs.
In Zanzibar [12], nine patients (seven treated with
ASAQ group and two with AL) developed clinically sus-
pected severe malaria and received rescue treatment.
These SAEs were associated with worsening conditions
and were thus not attributed to the study drugs.
Discussion
While not exhaustive, this is so far the largest dataset of
individual-patient tolerability data compiled on an ACT
(ASAQ); it includes a sizeable number of patients (nearly
6,200, enrolled in randomized controlled trials, almost
equally split between ASAQ and comparators groups)
with tolerability outcomes (adverse events, AEs), and is
representative of the spectrum composition of malaria
patients (it comprises mostly children under five years of
age (74%) from areas of moderate to high intensity of
malaria transmission of nine sub-Saharan African coun-
tries). In more than half of these patients (over 3,300),
events were recorded pre-treatment and graded in terms
of intensity, which allowed identifying and analysing
treatment emergent adverse events (TEAEs).
Both efficacy and tolerability information is essential
to guide treatment policy. However, while millions of
ACT treatments are given every year, and thousands of
patients are enrolled in trials with ACT, little tolerability
information is available. Tolerability data are often cur-
sorily presented in papers and difficult to standardize
and summarize. The availability of individual patient
data and the use of standardized methods for analysis
(including [17]) made it possible both to draw
generalizable conclusions and to identify site-specific
differences.Over 3,100 of these patients received ASAQ formu-
lated as different products (of whom over 2,100 were
treated with the loose or co-blistered and 1,000 with the
fixed dose combination) by various manufacturers.
Therefore, the conclusions reported here do not relate
to an individual drug product, but rather the collective
tolerability profile of ASAQ. Overall, the risk of experi-
encing an AE was not different in patients exposed to
ASAQ or other forms of ACT and non-ACT, with some
exceptions.
This analysis also provides important information on a
number of safety-related issues.
Risks varied across the different trial sites; clinical
safety appreciation differs from site to site and probably
from investigator to investigator. Also, the type of data
and the way they are collected varies. While standard
criteria exist [18], it would be useful to invest into har-
monizing both the variables collected, the timing of as-
sessment, and the grading of events, as well as the way
data are reported and analysed.
One particular example is vomiting. Vomiting is a
symptom of malaria, but can also be induced or made
worse by treatment. In studies where treatment is given
under direct observation it is possible to monitor the
patients for the first hour post-dosing in case drug is
vomited; this also allows re-administering the dose (in
toto or in part) when so required, and distinguishing be-
tween early and late vomiting [19]. Only one study pro-
vided for this [11]; all other relied upon subjects or
parent/guardians recall of episodes occurring in between
visits.
Multivariate logistic regression analysis, as well as the
comparison of TEAEs and AEs, pointed to the import-
ance of looking to the considerable background noise
generated by malaria itself (pretreatment and recur-
rence) as well as other diseases and conditions. For in-
stance, the risk of GI events in general (and more
specifically anorexia and diarrhoea) and other AEs
(weakness) was higher in patients with recurrent mal-
aria; cough (indicative of non-malaria infections)
increased with follow-up time; older age was associated
with a lower risk of most AEs.
It is important to distinguish the signs/symptoms of
malaria from those that may be caused by the treatment.
Assessing the drug-event relationship is highly subjective
and prone to bias. Recording the occurrence and severity
of (a defined set of ) events before treatment is adminis-
tered allows a better appreciation of the real contribution
of a treatment to a patient’s status. When this is done (in
this set of studies this involved ca. half of the patients en-
rolled), it is possible to report TEAE - ie the occurrence
post-treatment of a sign/symptom that was not present
before treatment, or its worsening with treatment. This
applies also to RCTs, where randomization is expected to
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ested not only on the relative (between-treatment) but
also the absolute risks for toxicity. These analyses
showed that the risks, when considering AEs over
TEAEs, ranged from no difference (rare events like jaun-
dice, tinnitus) to double (vomiting), triple (abdominal
pain), five-fold (nausea, headache, dizziness) differences.
The relationship with prevalence of signs/symptom at
enrolment was greater for AEs compared to TEAEs
(meaning that the definition of AE is less independent of
the sign/symptoms related to the disease itself ).
Traditionally, the main concern in malaria has been ef-
ficacy, which has driven treatment recommendations
(and a living databases of efficacy has been created [20]).
Safety and tolerability, instead, have been neglected.
Now with generally efficacious, intensely used ACT,
assessing safety risks has become as important as ever.
Compared to pharmaco-vigilance, clinical trials offer the
opportunity of closer, more detailed monitoring of
events, but are unsuited for signal generation (rare
events). Yet, monitoring and reporting on safety out-
comes in clinical trials is more cumbersome and less
standardized than for efficacy outcomes (and generally
felt by trialists to be less appealing). Paradoxically, this
has created situations whereby claims of toxicity based
on dubious evidence can cause a treatment to be dis-
liked, recommended against, or banned altogether.
In conclusion, this paper provides both (i) a compara-
tive evaluation of the safety risks following various ACT
on a large, representative sample of malaria patients; and
(ii) a proposal for improved methods to assess safety
risks.
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